Observational study of older patients with acute myeloid leukemia receiving intensive treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational epidemiological study focuses on patients aged 60 and over who are diagnosed with de novo or secondary acute myeloid leukemia (AML) and are eligible for intensive induction therapy. The study aims to gather data on the clinical and biological characteristics of these patients and correlate these factors with their treatment outcomes. Given the increasing incidence of AML with age, particularly after 50, the study seeks to understand the effectiveness of intensive chemotherapy in achieving complete remission and the long-term survival rates in this demographic. The research will involve collecting data from multiple centers to provide a comprehensive overview of this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged 60 and over
* Patients with previously untreated de novo or secondary AML
* Patients suitable for standard intensive treatment
* Patients who have read the information document and agreed to the collection of data concerning them (signature of informed consent).

Exclusion Criteria:

* Patients with AML 3
* Patients with severe, uncontrolled infection at the time of inclusion
* Patients with psychiatric or social disorders that will prevent compliance with the protocol
* Patients without health insurance (affiliation to a social security scheme)

Where it's running

• Angers CHU
  Angers, France Recruiting
• Annecy CH
  Annecy, France Recruiting
• Avignon CH
  Avignon, France Recruiting
• Bayonne CH
  Bayonne, France Recruiting
• Besançon CHU
  Besançon, France Recruiting
• Brest CHU
  Brest, France Recruiting

Study contacts

• Study coordinator: Ariane Mineur
• Email: ariane.mineur@chu-bordeaux.fr
• Phone: +33 (5)57 62 31 08

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Quality-of-life–guided red blood cell transfusions for people with refractory MDS or AML

  We test whether using routine EQ-5D-5L quality-of-life scores to decide when to give red blood cell transfusions can safely reduce the number of transfusions for adults with refractory MDS or AML who are receiving only palliative care.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice · NCT07328191

• Venetoclax plus Azacitidine versus Daunorubicin/Idarubicin plus Cytarabine induction for fit older adults with AML

  This trial will test whether Venetoclax plus Azacitidine works as well as standard daunorubicin or idarubicin plus cytarabine induction in fit adults aged 55–75 with acute myeloid leukemia.

  Recruiting Phase 3 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07132684

• Post-remission treatments for MRD-positive adult AML

  This study will try different drug regimens to see if they help people aged 14 and older with AML who are in remission but still MRD-positive stay relapse-free and live longer.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07131059

• Venetoclax plus a short (3-day) decitabine schedule for untreated elderly or unfit adults with AML

  This trial will see if venetoclax combined with a short (3-day) decitabine course helps people with newly diagnosed AML who are elderly or cannot receive standard chemotherapy.

  Recruiting The Second Hospital of Hebei Medical University · Hebei · NCT07117422

• Using eganelisib alone and with cytarabine for treating relapsed/refractory AML

  This study is testing if a new drug called eganelisib, used alone or with another drug called cytarabine, can help people with relapsed or hard-to-treat acute myeloid leukemia feel better.

  Recruiting at 12 sites Phase 1 Stelexis BioSciences · Duarte, California and 11 other locations · NCT06533761

• Real-world outcomes for adults with AML treated with new drugs (BoxTrial)

  This project will follow adults with AML treated in routine care across Italy to see how new approved drugs and combinations perform over at least two years.

  Recruiting at 2 sites Gruppo Italiano Malattie EMatologiche dell'Adulto · San Giovanni Rotondo and 1 other locations · NCT06513273

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.